Loading...
Loading...
BFRI| Name | Value |
|---|---|
| Revenues | 8,879.0K |
| Cost of Revenue | 4,495.0K |
| Gross Profit | 4,384.0K |
| Operating Expense | 9,021.0K |
| Operating I/L | -4,620.0K |
| Other Income/Expense | -1,721.0K |
| Interest Income | 13.0K |
| Pretax | -6,341.0K |
| Income Tax Expense | 1.0K |
| Net Income/Loss | -6,342.0K |
Biofrontera Inc. is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions in the United States. Its flagship product, Ameluz, is a prescription drug used in combination with the RhodoLED lamp series for photodynamic therapy to treat actinic keratosis. Additionally, the company offers Xepi, a prescription cream for impetigo treatment. Biofrontera generates revenue through the sale of these prescription drugs and medical devices, catering to the needs of patients with dermatological conditions.
